Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Diabetes drugs that mimic a signalling molecule called glucagon-like peptide-1 (GLP1) can control blood glucose levels, but they are short-lived in the body and have to be injected weekly. To make a GLP1 drug that lasts longer, Ashutosh Chilkoti at Duke University in Durham, North Carolina, and his colleagues fused GLP1 to a protein called ELP, which can be made to form a gel at specific temperatures.